October 5, 2017

    PENDOPHARM launches GLATECT, a new treatment option for MS patients

    Print

    MONTREAL, QUEBEC – October 4, 2017  On September 29th, Pendopharm, a division of Pharmascience Inc., launched PrGLATECT™ (glatiramer acetate for injection) in Canada – for the treatment or relapsing-remitting multiple sclerosis (RRMS) – in partnership with Synthon.

    GLATECT is indicated for the treatment of ambulatory patients with Relapsing Remitting Multiple Sclerosis (RRMS), including patients who have experienced a single demyelinating event and have lesions typical of multiple sclerosis on brain MRI:1 [PM, p. 3B, 14D]

    • To decrease the frequency of clinical exacerbations
    • To reduce the number and volume of active brain lesions identified on Magnetic Resonance Imaging (MRI) scans

    The safety and efficacy of GLATECT in chronic progressive MS have not been established.1 [PM, p. 3B, 14D]

    Canada has the highest rate of MS in the world, with an estimated 100,000 Canadians living with the disease. MS is a chronic disease of the central nervous system that is characterized by inflammation and neurodegeneration.2 [MS Society, p. 1A, 2B]

    “Multiple sclerosis disease-modifying drugs have revolutionized how we treat patients suffering from this disease, thus improving their quality of life,” says Jean-François Lemieux, VP and General Manager of Pendopharm, a division of Pharmascience Inc.

    “The launch of GLATECT, a subsequent version of the original glatiramer acetate, provides a therapeutically equivalent alternative for Canadian patients living with multiple sclerosis. This launch is a prime example of how Pendopharm, a Canadian company, contributes significantly to the sustainability of the health care system by making such therapies more accessible,” Lemieux adds.

     

    About Pendopharm

    Pendopharm, a division of Pharmascience Inc., aims to be a new partner in the treatment of MS in Canada. Pendopharm is strategically committed to growth and is actively engaged in licensing, partnering, developing, and marketing specialty prescription medicines, as well as consumer brands.

    About Synthon

    Synthon, headquartered in the Netherlands, is an international, science-centered pharmaceutical company specialized in developing and manufacturing high-quality generic and innovative medicines for patients around the world. Synthon products are currently approved by regulatory agencies in over 90 countries worldwide and marketed through strategic partnerships. For more information, please visit www.synthon.com.

     

    For Media Inquiries

    Steeve Azoulay

    Public Affairs and Communications

    Tel: 514-340-9800 ext. 7696

    sazoulay@pharmascience.com

     

    Patrick Corriveau

    Commercial Director, Hospital & Specialty Products

    Tel: 514-340-9800 ext. 5088

    pcorrive@pharmascience.com

     

    References: 1. GLATECT® Product Monograph. Pharmascience Inc. January 16, 2017. 2. MS Society of Canada: About MS. https://mssociety.ca/about-ms. Accessed: May 17, 2017.